BCR_ABL1, Female African doctor talking to female patient
Oncology | Blood Cancer

BCR::ABL1 Mbcr testing, whenever you need it

Offer oncologist-hematologists consistency in CML monitoring

BCR::ABL1 Mbcr fusion gene in CML monitoring

More than 95% of chronic myeloid leukemia (CML) cases have the BCR::ABL1 fusion gene.

Measuring BCR::ABL1 Mbcr levels enables oncologist-hematologists monitor CML effectively and make better informed management decisions. With the International Scale (IS) standardization of BCR::ABL1 Mbcr measurements, all providers on the patient journey can be sure they’re on the same page. BCR::ABL1 Mbcr testing also helps researchers advance CML clinical research.

More about CML
Two scientists working in a laboratory, focused on pipetting, Clinical Genomics
BCR::ABL1, International Scale

Reliably quantify BCR::ABL1 Mbcr transcripts

Our solutions let you reliably detect and quantify BCR::ABL1 Mbcr levels directly to the WHO International Scale (IS).

With the BCR::ABL1 Mbcr testing kits, you can be sure of:

  • Reliable quantitative detection of BCR::ABL1 Mbcr e14a2 (b3a2) & e13a2 (b2a2)  fusion gene transcripts
  • Direct results alignment on the international scale in every run and reporting molecular response status
  • Inter-lab harmonization in CML monitoring
  • Consistent results and increased lab efficiency
  • An Integrated, ready-to-use workflow that saves time and lowers costs

IS-standardized testing with ipsogen BCR::ABL1 Mbcr kits

The ipsogen BCR-ABL1 Mbcr IS-MMR and ipsogen BCR-ABL1 Mbcr RGQ RT-PCR kits let you accurately monitor the molecular response on the established WHO IS in patients diagnosed with Ph+ CML.

With the kits, you get:

  • Quantitative measurement of the BCR::ABL1 Mbcr fusion gene e14a2 (b3a2) & e13a2 (b2a2) transcripts in total RNA extracted from whole blood
  • Direct conversion of results in every run to the established World Health Organization (WHO) IS and reporting of molecular response status

Browse our region-specific BCR::ABL1 Mbcr tests

ipsogen (1)
ipsogen BCR-ABL1 Mbcr IS-MMR Kits CE
oncology ipsogen leukemia
ipsogen BCR-ABL1 Mbcr IS-MMR Kits CE
For the quantification of BCR-ABL1 Mbcr b3a2 & b2a2 fusion gene transcripts and results alignment on the international scale
In line with established HUGO Gene Nomenclature Committee (HGNC) recommendations for the fusion gene nomenclature (Bruford EA, et al. Leukemia. 2021, https://doi.org/10.1038/s41375-021-01436-6), we are implementing use of italics and double colon (::) for fusion genes designation (e.g. BCR::ABL1). However historical nomenclature (e.g. BCR-ABL1) may persist in our materials.